Efficacy and Safety of Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: Results From a Pivotal Open-Label Study with a Median Follow-Up of ≥2 Years
Emily S. Ruiz, MD, MPH, FAAD discusses efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a pivotal open-label study with a median follow-up of ≥2 years.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.